Summary The sensitivity of eight cell lines established from treated and untreated patients with small cell carcinoma of the lung (SCCL) was tested in the clonogenic assay with 1 h and continuous exposure to aclarubicin (ACLA), adriamycin (ADR), daunorubicin (DAU) and mitoxantrone (MITO). The sensitivity to ADR, DAU and MITO covariated, and varied with a factor of five. The sensitivity to ACLA was independent of the sensitivity to ADR and varied only within a factor of two. Only ACLA showed pronounced increased potency with continuous incubation, and ACLA was the most potent drug in the three cell lines least sensitive to ADR. Two resistant cell lines were selected by treating NCI-H69 in vitro with DAU. One cell line (9-fold resistant to DAU) expressed large amounts of P-glycoprotein, the other cell line (4-fold resistant to DAU) had barely detectable glycoprotein. Both lines acquired resistance to ADR, ACLA and MITO. The cross-resistance to ACLA and MITO was only partial and ACLA was still the most potent drug on these lines. The sensitivity to ACLA of the cell lines least sensitive to ADR suggest that ACLA partially circumvents mechanisms of multidrug resistance. Together with the pronounced increase in potency with prolonged exposure, these results suggest that ACLA has a mechanism of action different from the 'classical' anthracyclines. In this context mitoxantrone is more similar to the classical anthracyclines although its structure is more dissimilar.
The anthracyclines are among the most potent drugs in the treatment of a wide range of human neoplasms. Development of resistance to the drugs is a major problem, and much effort is devoted to the search of new anthracyclines without cross-resistance to the parent drugs. The anthracycline aclarubicin (ACLA) was isolated in 1975 by Oki et al. (1975) and activitiy was found in acute myelogenic leukaemia (AML) refractory to treatment with daunorubicin (DAU) and cytarbine (Pedersen-Bjergaard et al., 1984; Warrel et al., 1982) . Recently, a phase III trial has found ACLA to be superior to DAU in the treatment of de novo AML (Hansen et al., 1988) . In a previous study on the inter-experimental variation in the clonogenic assay we observed that the sensitivity pattern to ACLA in a panel of small cell lung cancer (SCCL) cell lines was different from the sensitivity to adriamycin (ADR), DAU and mitoxantrone (MITO) after short time incubation (Jensen et al., 1989 ). The present investigations were initiated to further elucidate the differences between ACLA and the other analogues. A murine tumour has recently been described to be relatively more sensitive to MITO than the tested human tumours (Hill et al., 1989) . The murine tumour cells P388 and Ehrlich were included in the present study for comparision to the human cell lines and the in vivo antitumour models. As the relationship between duration of drug exposure and cytotoxicity can give valuable information on mechanisms of toxicity (Roed et al., 1986) , the patterns of sensitivity to ACLA, ADR, DAU and MITO after short time exposure were compared with the cytotoxicity and cross-resistance patterns after prolonged administration.
Two DAU resistant SCCL cell lines with pronounced differences in expression of the multidrug resistant (MDR) related P-glycoprotein were selected in vitro and compared to the parental line.
Materials and methods
Drugs ADR (Carlo Erba), DAU (Rhone Poulenc) and ACLA (Lundbeck) were dissolved in sterile water just before use. MITO (Lederle) was supplied in aqueous solution for infusion. Drug solutions were made with tissue culture medium.
Cell lines
The human SCCL cell lines used were NCI-H69, NCI-N592, NCI-H249CL5, NCI-N417, OC-NYH (also designated GLC-2), OC-TOL (GLC-3), GLC-16 and SCLC-86M1. Their source, relation to therapy and growth behaviour in vitro are described in Table I . The serially transplanted mouse tumours Ehrlich ascites tumour and P388 leukaemia were transferred to medium and established as in vitro cell lines without changes in DNA content. After three passages in vitro the cell lines were used in experiments. Resistance to DAU was obtained by treating a total of approximately 5 x 10' NCI-H69 cells with 0.1 Lg ml-' of DAU continuously. The surviving cells were pooled and passaged three times in medium with 0.1 lg ml-' DAU. Cell line NCI-H69 /DAU4 was maintained in drug-free medium for 4 weeks before testing. Cell line NCI-H69/DAU8 was maintained in drug-free medium for 8 weeks before testing.
All cell lines were maintained at 37°C in Roswell Park Memorial Institute medium 1640 with 10% fetal calf serum in a humidified atmosphere with 7.5% CO2. The cell lines were free of mycoplasm contamination, and the genetic stability of the cell lines was checked by flow cytometric DNA-analysis. Flow cytometric DNA-analysis Cell samples for flow cytometric DNA-analysis were taken from the single-cell suspensions just before drug exposure. After centrifugation, the cells were suspended in citrate buffer, frozen on ethanol with dry ice and stored at -80°C until analysis (Vindel0v et al., 1983a) . The samples were stained with propidium iodide (Vindel0v et al., 1983b ) and analysed in a FACS III flow-cytometer (Becton-Dickinson).
The percentage of cells in each cell cycle phase was determined by statistical analysis of the DNA distribution (Christensen et al., 1978) .
Immunological detection of P-glycoprotein C219 monoclonal antibody (1 mg ml-') against Pglycoprotein (Kartner et al., 1985) was purchased from Centocor (Malvern, PA, USA). Peroxidase conjugated antibody was purchased from Dakopatts, Copenhagen.
Western blot Cells from all human cell lines were spun down at 150 g and washed with PBS. The cell pellets were then resuspended (v/v 2:3) in a solution consisting of 3.4 mM sodium citrate, 1.5 mM spermine tetrahydrochloride, 0.5 mM Tris and 1% v/v Nonidet P40 (pH 7.6). After centrifugation at 1,400 g, 35 fil of the supernatants were loaded on to a 10% (w/w) SDS-PAGE gel with 0.1% (w/w) SDS. Proteins were blotted on to nitrocellulose paper after electrophoresis.
The paper was washed in a 150 mM NaCl, 50 mM Tris (pH 7.4) buffer containing 3% (w/w) bovine serum albumin, and 0.1% (v/v) Tween 20, and probed overnight at 4°C with the C219 antibody at 1:400 dilution. Peroxidase conjugated rabbit anti-mouse antibody (Dako P260) was used as the secondary antibody at a dilution of 1:250 applied for 2 h. The blot was developed using 3-amino-9-ethyl carbazole as chromogen. Controls were performed by omission of the primary antibody.
Immunohistochemistry Cell from all human lines were pelleted and frozen sectioned. Frozen sections were fixed in acetone for 15min. Thereafter a three layer immunohistochemical technique was employed, the first layer being C219 antibody 1:500 overnight at 4°C, the second layer peroxodise conjugated rabbit anti-mouse 1:10 (Dako P260), and the third layer peroxidase conjugated swine anti-rabbit 1:20 (Dako P217) with washes of PBS in between. 3-Amino-9-ethyl carbazole was used as chromogen and Mayer's haematoxylin counterstain. Controls were performed by omission of the primary antibody.
Results
We have previously shown that the sensitivity of the SCCL cell lines to ADR, DAU and MITO with 1-h incubation is dependent on the size of the S-phase fraction at the time of drug exposure and that reduced variation in the clonogenic assay can be obtained by standardisation of the cell culture conditions (Jensen et al., 1989) . In the present study, the inter-experimental variation after continuous incubation was evaluated on cell line NCI-N592 in three experiments with varying S-phase distribution (Table II) . Despite a variation with a factor of two in the S-phase distribution, the interexperimental variation in LD50 is less than 25% and not correlated to the size of the S-phase. With similar S-phase variations the sensitivity with 1-h incubation varied 250% (Jensen et al., 1989 (Hill et al., 1989) . Although is relatively more sensitive to DAU, the sensitivity to ADR and DAU covariate and is almost equal in most cell lines, whereas DAU is more potent than ADR with 1-h incubation.
MITO is a potent drug with continuous incubation and the lines, the patterns of 1-h incubation and continuous incubation indicate cross-resistance between ADR, DAU and MITO, whereas the sensitivity pattern to ACLA is different.
With 1-h incubation, the average LD50 value obtained with ACLA on the 10 cell lines is 0.39 lgml-' and with continuous incubation it was 0.077 gg ml-'. The potency of ACLA is thus increased by a factor of 51. The potency of MITO, ADR and DAU are increased by factors of only 16, 13 and 6 respectively. The sensitivity of the DAU resistant cell lines NCI-H69/ DAU4 and NCI-H69/DAU8 was assessed with continuous incubation (Figure 3) . Compared to the parental line, the resistant cell lines are cross-resistant to ADR and partially resistant to MITO and ACLA. Resistance to anthracyclines has been attributed to a 'leak and pump' model of the cell membrane with an active efflux of the anthracyclines proposed to be linked to a glycoprotein (P-glycoprotein) in the cell membrane (Bradley et al., 1988) . Western blot analysis with the monoclonal antibody C-219 directed against the P-glycoprotein was performed on all the human cell lines. There was no detectable staining for P-glycoprotein on the wild type lines (not shown). In the resistant lines there was barely detectable glycoprotein on NCI-H69/DAU8 whereas the glycoprotein was clearly discernible on cell line NCI-H69/ DAU4 (Figure 4 ). Based on the dilution shown in Figure 4 the limit of detection is between 5 and 10% of the amount seen in NCI-H69/DAU4, and it is seen that NCI-H69/DAU8 has less than 10% of the P-glycoprotein found in NCI-H69/ DAU4. Likewise the use of immunohistochemistry did not recognise P-glycoprotein on the wild type cell lines or on NCI-H69/DAU8 and confirmed the Western blot detection of P-glycoprotein in NCI-H69/DAU4 (not shown). In this panel of eight SCCL cell lines established from treated and untreated patients the sensitivities to the four drugs vary within a factor of only five. Thus, a minimal interexperimental variation is necessary in establishing sensitivity profiles from a panel of cell lines. With short time incubation, the variation is mainly due to variations in the S-phase fraction. Consequently it is necessary to standardise growth conditions before sensitivity testing to reduce the variation in the S-phase fraction. The present investigation has shown that the inter-experimental variation with continuous incubation is small and not correlated to the size of the S-phase fraction at the start of the incubation. This finding is in accordance with the longer drug exposure time, ensuring that all cells pass through sensitive cell-cycle phases.
The almost identical sensitivity patterns obtained after 1-h incubation and continuous incubation strongly support the value of continuous incubation. A limited drug stability leading to poorly defined concentration-time products is, however, an obvious problem in interpreting data from experiments with continuous incubation. There seem to be no major differences in the stability of DAU, ACLA and MITO is physiological solutions. Thus DAU, ACLA and MITO are 95% stable in neutral 150 mM NaCl solutions at room temperature for 40, 52 and more than 48 h respectively (Bosanquet, 1986) . As shown by Bosanquet, no consensus exists in the literature regarding the stability of ADR, which has been most extensively studied, and it is suggested that similar discrepancies would be found if the other drugs were investigated as intensively. Therefore we tested the stability of the cytotoxicity of DAU and ACLA by comparing the 
Mol Figure 4 Western blot detection of P-glycoprotein with C219 monoclonal antibody. 1, P388 sensitive and, 2, P388/DAU + daunorubicin resistant murine controls. In the sensitive line C219 binds to protein with a lower molecular weight than Pglycoprotein; 3, the parental cell line NCI-H69; 4, subline NCI-H69/DAU8; 5, subline NCI-H69/DAU4; 6, 75%; 7, 50%; 8, 25%; 9, 10%; 10, 5% dilution of the protein loaded to lane 5; 11, Ehrlich/DAU + daunorubicin resistant and 12, wild type Ehrlich ascites tumour murine controls. activity of freshly diluted drugs with drugs preincubated for 48 h at 37°C in medium. In two experiments on cell lines NCI-H69 and NCI-N592 with 1-h drug exposure we found a 20 and 25% increase in the LD50 value of ACLA and a 3 and 5% increase in the LD50 value of preincubated DAU. Thus the relative increase in potency with continuous incubation cannot be explained by a higher stability of ACLA than of DAU. A possible explanation of the increase in potency elicited by ACLA with prolonged exposure time could be that ACLA preferentially inhibit RNA synthesis, especially nucleolar RNA synthesis (Skovsgaard, 1987; Oki et al., 1981) , in contrast to ADR and DAU, which inhibit DNA-and RNA-synthesis to almost the same degree.
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In vitro resistance and cross-resistance to ACLA have been studied in a number of anthracycline-resistant murine and human tumour cell lines (Table III) . Development of resistance to ACLA in the L5178Y cell line was accompanied by a reduction in the sensitivity to DAU and ADR (Nishimura et al., 1980) . However, only minimal cross-resistance was found in a range of human and murine cancer cell lines highly resistant to DAU and ADR (Nishimura et al., 1978; Hill et al., 1985; Umezawa et al., 1987; Scott et al., 1986; Twentyman et al., 1986) (Table III) . In vivo, ACLA was found to be effective in P388 resistant to m-AMSA (Johnson & Howard, 1982) and some activity was reported on P388 resistant to ADR (Oki et al., 1981) . In contrast, ACLA was ineffective in vivo against Ehrlich ascites tumour resistant to DAU (Skovsgaard, 1987) . We have compared the DAU resistant subline of Ehrlich ascites tumour to the wild type in vitro. The LD50 of ACLA was increased by a factor of 2.3 whereas a 20-fold increase was found with DAU. Since the Ehrlich wild type is not very sensitive to ACLA, such a low decrease in ACLA sensitivity is sufficient to result in total loss of activity. The sublines NCI-N69/DAU4 and NCI-H69/ DAU8 are cross-resistant not only to ADR and MITO, but also to ACLA. However, as seen in Figure 3 , both H69/ DAU8 and H69/DAU4 are more sensitive to ACLA than to (Aabo et al., 1983; Woolley et al., 1982; Kerpel-Fronius et al., 1987) including SCCL (Lev & Posada, 1983; Kramer et al., 1986; Abeloff et al., 1985) . The doses have invariably been significantly lower in the solid tumour trials (e.g. 100 mg m-2 as a bolus treatment) compared to the high doses of ACLA that have been used in leukaemia trials (e.g. 80 mg m-2 for three consecutive days). In this context it has been demonstrated (Machover et al., 1984) that the cumulative dose required for the majority of previously treated leukaemia patients to achieve complete remission is > 300 mg m2. Machover et al. (1984) used 10-day courses of ACLA at a daily dose of 15 mg m-2 with 10-day intervals between courses. This regimen was given to 25 patients with AML who were either refractory to initial induction chemotherapy or in relapse. Eleven patients (44%) achieved complete remission. These results are comparable to the results obtained with shorter schedules using considerably higher doses. Although optimal schedules cannot be determined in vitro, the present study also indicates a relative increase in ACLA potency with prolonged administration. However, the importance of a prolonged schedule still remains to be determined in a randomised trial.
If sensitivity patterns on cell lines obtained from treated and untreated patients with SCCL give a reliable picture of the disease, the lack of ACLA resistance on the panel of SCCL cell lines and the potency of ACLA seen with prolonged administration justify new clinical trials of ACLA against SCCL. In favour of this approach is also the great difficulty in obtaining in vitro resistance to ACLA that has been described from different groups. Tapiero et al. (1988) took 3 years to obtain a 6-fold ACLA resistant cell line, whereas a 100-fold ADR resistant cell line was obtained in a month. Likewise, Nishimura et al. (1980) tried without success to isolate ACLA resistant cells in vitro. We have recently initiated a phase II trial of ACLA on patients with relapse of SCCL using the high leukaemia doses in a three day schedule as this schedule has been most thoroughly tested.
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